Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Smoldering Multiple Myeloma 1 Salivary Gland Adenoma, Pleomorphic 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Monoclonal Gammopathy of Undetermined Significance 1 Liver Cirrhosis 1 Glioma 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Temozolomide 42 Magnetic Resonance Spectroscopy 41 Radiotherapy 22 Specimen Handling 18 Biopsy 13 X-Rays 10 Radiation 10 trametinib 8 Bevacizumab 8 Nivolumab 7 Blood Specimen Collection 7 olaparib 6 fluorodopa F 18 6 dabrafenib 6 Radiotherapy, Intensity-Modulated 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 6 Lomustine 6 pembrolizumab 5 abemaciclib 5 Standard of Care 5 vorasidenib 4 ulixertinib 4 larotrectinib 4 ivosidenib 4 erdafitinib 4 Surgical Procedures, Operative 4 Dianhydrogalactitol 4 Cyclophosphamide 4 Aminolevulinic Acid 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioma × Urination × 1 year × Clear all

NCT06575452 2025-12-03

EPIGLIO

Institut du Cancer de Montpellier - Val d'Aurelle

Phase NA Not yet recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡